Dot for all patients with smear-positive pulmonary TB in London? [1]

Thorax

Volumn 58, Issue 1, 2003, Pages 91-

  Barker, R D ^a   Glyn Jones, J ^a   Bothamley, G ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

DIRECTLY OBSERVED THERAPY; DISEASE TRANSMISSION; HUMAN; LETTER; LUNG TUBERCULOSIS; PRIORITY JOURNAL; SCREENING; SMEAR; UNITED KINGDOM;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; TUBERCULOSIS, PULMONARY;

EID: 0037259502     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.1.91     Document Type: Letter

References (17)

1. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002;57:477-82.
2. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City: turning the tide. N Engl J Med 1995;333:229-33.
3. Maguire H, Dale JW, McHugh TD, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002;57:617-22.
4. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-8.
5. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001;56:173-9.
6. Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998;352:1340-3.
7. Walley JD, Khan MA, Newell JN, et al. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001;357:664-9.
8. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999;93:552-7.
9. Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997;111:1168-73.
10. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ 1997;315:1403-6.
11. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000;355:1345-50.
12. Bothamley GH, Rowan JP, Griffiths CJ, et al. Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless. Thorax 2002;57:45-9.
13. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spotial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357:2017-21.
14. NHS Executive. Tuberculosis control in London: the need for change. A report for the Thames Regional Directors of Public Health, London, 1998.
15. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000;55:962-3.
16. Rose AM, Sinka K, Watson JM, et al. An estimate of the contribution of HIV infection to the recent rise in tuberculosis in England and Wales. Thorax 2002;57:442-5.
17. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.